Mergers May Buy Time, But Fundamental Change Is Necessary, GSK’s Garnier
Executive Summary
The spate of large scale mergers at the beginning of the decade provided companies with time to deal with patent expirations, but ultimately firms need to fundamentally change their business model, GlaxoSmithKline CEO J.P. Garnier said
You may also be interested in...
Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial
Roche is taking a dual approach in reorganizing its global R&D business by centering on key disease areas and consolidating its full operations, from R&D to marketing, along those lines
GSK Sees New Round Of “Defensive Mergers” Ahead, CEO Says
GlaxoSmithKline sees another round of defensive mergers coming in the pharmaceutical industry, CEO J.P. Garnier declared during a securities analysts meeting in London Feb. 14
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue